First Horizon Corp Buys 89,074 Shares of Bristol Myers Squibb Company $BMY

First Horizon Corp increased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 72.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 211,395 shares of the biopharmaceutical company’s stock after purchasing an additional 89,074 shares during the period. First Horizon Corp’s holdings in Bristol Myers Squibb were worth $12,821,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Bayban purchased a new position in Bristol Myers Squibb during the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb was added to the Russell 1000 Defensive and Russell 1000 Value-Defensive indexes, which could broaden support from defensive and income-focused funds and reinforce its appeal as a lower-volatility dividend stock. Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY?
• Positive Sentiment: The company’s QUILS lung cancer detection initiative is expanding beyond Kentucky into other high-risk states, highlighting Bristol Myers Squibb’s broader oncology focus and potential reputational benefits for its public-health efforts. Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research report on Monday. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 2nd. Finally, Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $57.89 on Friday. The business’s 50 day moving average price is $56.83 and its 200 day moving average price is $57.62. The company has a market cap of $118.21 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 0.16 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the prior year, the business earned $1.80 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.